Tonix Pharma Files 8-K: Officer/Director Changes & Compensation
Ticker: TNXP · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1430306
| Field | Detail |
|---|---|
| Company | Tonix Pharmaceuticals Holding Corp. (TNXP) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, compensation
Related Tickers: TNXP
TL;DR
TONIX leadership shakeup and pay details just dropped in an 8-K.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on June 13, 2025, reporting on events from June 12, 2025. The filing indicates changes in directors or officers, the election of directors, the appointment of certain officers, and details compensatory arrangements. It also covers other events and financial statements/exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and executive compensation, which can significantly impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in corporate leadership and compensation can signal internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- June 12, 2025 (date) — Earliest event reported
- June 13, 2025 (date) — Filing date
- 26 Main Street, Chatham, New Jersey, 07928 (address) — Principal executive office address
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, though specific names are not detailed in this excerpt.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on significant corporate events including changes in directors/officers, elections, appointments, compensatory arrangements, and other material events.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 12, 2025.
What is the company's state of incorporation and fiscal year end?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada and its fiscal year ends on December 31.
What is the company's principal executive office address?
The principal executive office is located at 26 Main Street, Suite 101, Chatham, New Jersey, 07928.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).